The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis

Journal of Genetics and Genomics

Volumn 40, Issue 7, 2013, Pages 347-354

  Kong, Sinyi ^a   Yeung, Pricilla ^a   Fang, Deyu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Epigenetic; Rheumatoid arthritis; Sirt1

Indexed keywords

RESVERATROL; SIRTUIN 1; TRANSCRIPTION FACTOR FOXO;

ACETYLATION; ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; CARTILAGE CELL; CARTILAGE DEGENERATION; FIBROBLAST; GENETIC TRANSCRIPTION; HUMAN; HYPERPLASIA; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; INNATE IMMUNITY; MACROPHAGE FUNCTION; NEGATIVE FEEDBACK; NONHUMAN; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EPIGENETIC; RHEUMATOID ARTHRITIS; SIRT1;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNE TOLERANCE; MACROPHAGES; SIRTUIN 1; STILBENES; T-LYMPHOCYTES;

MUS;

EID: 84880616633     PISSN: 16738527     EISSN: 18735533     Source Type: Journal    
DOI: 10.1016/j.jgg.2013.04.001     Document Type: Review

References (98)

1. Afshar G., Murnane J.P. Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2. Gene 1999, 234:161-168.
2. Alcaín F.J., Villalba J.M. Sirtuin activators. Expert Opin. Ther. Pat. 2009, 19:403-414.
3. Bach F.H., Bach M.L., Sondel P.M. Differential function of major histocompatibility complex antigens in T-lymphocyte activation. Nature 1976, 259:273-281.
4. Bartok B., Firestein G.S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 2011, 233:233-255.
5. Bonizzi G., Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25:280-288.
6. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280:17187-17195.
7. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., Tran H., Ross S.E., Mostoslavsky R., Cohen H.Y., Hu L.S., Cheng H.L., Jedrychowski M.P., Gygi S.P., Sinclair D.A., Alt F.W., Greenberg M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
8. Byun H.S., Song J.K., Kim Y.-R., Piao L., Won M., Park K.A., Choi B.L., Lee H., Hong J.H., Park J., Seok J.H., Lee Y.J., Kang S.W., Hur G.M. Caspase-8 has an essential role in resveratrol-induced apoptosis of rheumatoid fibroblast-like synoviocytes. Rheumatology 2008, 47:301-308.
9. Calfon M., Zeng H., Urano F., Till J.H., Hubbard S.R., Harding H.P., Clark S.G., Ron D. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 2002, 415:92-96.
10. Chen L.-f., Mu Y., Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J. 2002, 21:6539-6548.
11. + suppressor T cells induced by tolerogenic conjugates of antigen and mPEG. Cell. Immunol. 1993, 149:409-421.
12. Cheng H.L., Mostoslavsky R., Saito S., Manis J.P., Gu Y., Patel P., Bronson R., Appella E., Alt F.W., Chua K.F. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. USA 2003, 100:10794-10799.
13. Droin N.M., Pinkoski M.J., Dejardin E., Green D.R. Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. Mol. Cell. Biol. 2003, 23:7638-7647.
14. Dvir-Ginzberg M., Gagarina V., Lee E.J., Booth R., Gabay O., Hall D.J. Tumor necrosis factor α-mediated cleavage and inactivation of SirT1 in human osteoarthritic chondrocytes. Arthritis Rheum. 2011, 63:2363-2373.
15. Elmali N., Baysal O., Harma A., Esenkaya I., Mizrak B. Effects of eesveratrol in inflammatory arthritis. Inflammation 2007, 30:1-6.
16. Fang D., Elly C., Gao B., Fang N., Altman Y., Joazeiro C., Hunter T., Copeland N., Jenkins N., Liu Y.C. Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation. Nat. Immunol. 2002, 3:281-287.
17. Fang D., Wang H.Y., Fang N., Altman Y., Elly C., Liu Y.C. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J. Biol. Chem. 2001, 276:4872-4878.
18. Fiocco U., Sfriso P., Lunardi F., Pagnin E., Oliviero F., Scagliori E., Cozzi L., Vezzu M., Molena B., Scanu A., Panziera C., Nardacchione R., Rubaltelli L., Dayer J.M., Calabrese F., Punzi L. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis. Autoimmun. Rev. 2011, 9:780-784.
19. Foletta V., Segal D., Cohen D. Transcriptional regulation in the immune system: all roads lead to AP-1. J. Leukoc. Biol. 1998, 63:139-152.
20. Fujisawa K., Aono H., Hasunuma T., Yamamoto K., Mita S., Nishioka K. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α. Arthritis Rheum. 1996, 39:197-203.
21. Gao B., Kong Q., Kemp K., Zhao Y.S., Fang D. Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2-mediated reversal of T-cell tolerance. Proc. Natl. Acad. Sci. USA 2012, 109:899-904.
22. Gao Z., Ye J. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem. Biophys. Res. Commun. 2008, 376:793-796.
23. Grabiec A.M., Tak P.P., Reedquist K.A. Function of histone deacetylase inhibitors in inflammation. Crit. Rev. Immunol. 2011, 31:233-263.
24. Guerder S., Picarella D.E., Linsley P.S., Flavell R.A. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor α leads to autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA 1994, 91:5138-5142.
25. + T cells. J. Immunol. 2004, 173:7331-7338.
26. Holoshitz J., Matitiau A., Cohen I.R. Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria but not to collagen type II. J. Clin. Invest. 1984, 73:211-215.
27. Hoyne G.F. Mechanisms that regulate peripheral immune responses to control organ-specific autoimmunity. Clin. Dev. Immunol. 2011, 2011:294968.
28. Hu P., Han Z., Couvillon A.D., Kaufman R.J., Exton J.H. Autocrine tumor necrosis factor α links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1α-mediated NF-κB activation and down-Regulation of TRAF2 expression. Mol. Cell. Biol. 2006, 26:3071-3084.
29. Hu X., Chakravarty S.D., Ivashkiv L.B. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol. Rev. 2008, 226:41-56.
30. Huang Q.Q., Sobkoviak R., Jockheck-Clark A.R., Shi B., Mandelin A.M., Tak P.P., Haines G.K., Nicchitta C.V., Pope R.M. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. J. Immunol. 2009, 182:4965-4973.
31. Huang W., Shang W.L., Wang H.D., Wu W.W., Hou S.X. Sirt1 overexpression protects murine osteoblasts against TNF-alpha-induced injury invitro by suppressing the NF-κB signaling pathway. Acta Pharmacol. Sin. 2012, 33:668-674.
32. Imai S., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.
33. + cells, and decreased macrophage IL-6 expression. Int. Immunopharmacol. 2009, 9:134-143.
34. Jain J., McCaffrey P.G., Valge-Archer V.E., Rao A. Nuclear factor of activated T cells contains Fos and Jun. Nature 1992, 356:801-804.
35. Jain J., Valge-Archer V.E., Rao A. Analysis of the AP-1 sites in the IL-2 promoter. J. Immunol. 1992, 148:1240-1250.
36. Jain J., Valge-Archer V.E., Sinskey A.J., Rao A. The AP-1 site at -150 bp, but not the NF-κB site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter. J. Exp. Med. 1992, 175:853-862.
37. Jung S., Yaron A., Alkalay I., Hatzubai A., Avraham A., Ben-Neriah Y. Costimulation requirement for AP-1 and NF-κB transcription factor activation in T cells. Ann. N. Y. Acad. Sci. 1995, 766:245-252.
38. Kang S.M., Beverly B., Tran A.C., Brorson K., Schwartz R.H., Lenardo M.J. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 1992, 257:1134-1138.
39. Kok S.H., Lin L.D., Hou K.L., Hong C.Y., Chang C.C., Hsiao M., Wang J.H., Lai E.H., Lin S.K. Simvastatin inhibits Cyr61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of SIRT1/FoxO3a signaling. Arthritis Rheum. 2013, 65:639-649.
40. Kong S., Kim S.-J., Sandal B., Lee S.-M., Gao B., Zhang D.D., Fang D. The type III histone deacetylase Sirt1 protein suppresses p300-mediated histone H3 lysine 56 acetylation at Bclaf1 promoter to inhibit T cell activation. J. Biol. Chem. 2011, 286:16967-16975.
41. Lazarevic V., Zullo A.J., Schweitzer M.N., Staton T.L., Gallo E.M., Crabtree G.R., Glimcher L.H. The gene encoding early growth response 2, a target of the transcription factor NFAT, is required for the development and maturation of natural killer T cells. Nat. Immunol. 2009, 10:306-313.
42. Lee S.M., Yang H., Tartar D., Gao B., Luo X., Ye S., Zaghouani H., Fang D. Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia 2011, 54:1136-1146.
43. Lenschow D.J., Zeng Y., Thistlethwaite J.R., Montag A., Brady W., Gibson M.G., Linsley P.S., Bluestone J.A. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992, 257:789-792.
44. Lin L., Hron J.D., Peng S.L. Regulation of NF-κB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity 2004, 21:203-213.
45. Lin Z., Yang H., Kong Q., Li J., Lee S.M., Gao B., Dong H., Wei J., Song J., Zhang D.D., Fang D. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol. Cell 2012, 46:484-494.
46. Liszt G., Ford E., Kurtev M., Guarente L. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J. Biol. Chem. 2005, 280:21313-21320.
47. Macián F., GarcIa-Cózar F., Im S.-H., Horton H.F., Byrne M.C., Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002, 109:719-731.
48. Manna S.K., Mukhopadhyay A., Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 2000, 164:6509-6519.
49. Marok R., Winyard P.G., Coumbe A., Kus M.L., Gaffney K., Blades S., Mapp P.I., Morris C.J., Blake D.R., Kaltschmidt C., Baeuerle P.A. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum. 1996, 39:583-591.
50. Martinon F., Chen X., Lee A.H., Glimcher L.H. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat. Immunol. 2010, 11:411-418.
51. McBurney M.W., Yang X., Jardine K., Bieman M., Th'ng J., Lemieux M. The absence of SIR2alpha protein has no effect on global gene silencing in mouse embryonic stem cells. Mol. Cancer Res. 2003, 1:402-409.
52. McInnes I.B., Liew F.Y., Gracie J.A. Interleukin-18: a therapeutic target in rheumatoid arthritis?. Arthritis Res. Ther. 2005, 7:38-41.
53. Mondino A., Whaley C.D., DeSilva D.R., Li W., Jenkins M.K., Mueller D.L. Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB, and JunB in anergic T helper 1 cells. J. Immunol. 1996, 157:2048-2057.
54. Moon M.H., Jeong J.K., Lee Y.J., Seol J.W., Jackson C.J., Park S.Y. SIRT1, a class III histone deacetylase, regulates TNF-α-induced inflammation in human chondrocytes. Osteoarthritis Cartilage 2013, 21:470-480.
55. Morand E.F. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern. Med. J. 2005, 35:419-426.
56. Motta M.C., Divecha N., Lemieux M., Kamel C., Chen D., Gu W., Bultsma Y., McBurney M., Guarente L. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004, 116:551-563.
57. Nakayama H., Yaguchi T., Yoshiya S., Nishizaki T. Resveratrol induces apoptosis MH7A human rheumatoid arthritis synovial cells in a sirtuin 1-dependent manner. Rheumatol. Int. 2012, 32:151-157.
58. Niederer F., Ospelt C., Brentano F., Hottiger M.O., Gay R.E., Gay S., Detmar M., Kyburz D. SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. Ann. Rheum. Dis. 2011, 70:1866-1873.
59. Ofosu-Appiah W.A., Warrington R.J., Wilkins J.A. Interleukin 2 responsive T cell clones from rheumatoid and normal subjects: proliferative responses to connective tissue elements. Clin. Immunol. Immunopathol. 1989, 50:264-271.
60. Ohori M. ERK inhibitors as a potential new therapy for rheumatoid arthritis. Drug News Perspect. 2008, 21:245-250.
61. Oppenheimer H., Gabay O., Meir H., Haze A., Kandel L., Liebergall M., Gagarina V., Lee E.J., Dvir-Ginzberg M. 75-kd sirtuin 1 blocks tumor necrosis factor α-mediated apoptosis in human osteoarthritic chondrocytes. Arthritis Rheum. 2012, 64:718-728.
62. Powell J.D., Lerner C.G., Ewoldt G.R., Schwartz R.H. The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J. Immunol. 1999, 163:6631-6639.
63. Price Nathan L., Gomes Ana P., Ling Alvin J.Y., Duarte Filipe V., Martin-Montalvo A., North Brian J., Agarwal B., Ye L., Ramadori G., Teodoro Joao S., Hubbard Basil P., Varela Ana T., Davis James G., Varamini B., Hafner A., Moaddel R., Rolo Anabela P., Coppari R., Palmeira Carlos M., de Cabo R., Baur Joseph A., Sinclair David A. SIRT1 is required for AMPK activation and the beneficial effects of Resveratrol on mitochondrial function. Cell Metab. 2012, 15:675-690.
64. Recio M.C., Andujar I., Rios J.L. Anti-inflammatory agents from plants: progress and potential. Curr. Med. Chem. 2012, 19:2088-2103.
65. Rengarajan J., Mittelstadt P.R., Mages H.W., Gerth A.J., Kroczek R.A., Ashwell J.D., Glimcher L.H. Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity 2000, 12:293-300.
66. Rincon M., Flavell R.A. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J. 1994, 13:4370-4381.
67. Roelofs M.F., Boelens W.C., Joosten L.A., Abdollahi-Roodsaz S., Geurts J., Wunderink L.U., Schreurs B.W., van den Berg W.B., Radstake T.R. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J. Immunol. 2006, 176:7021-7027.
68. Safford M., Collins S., Lutz M.A., Allen A., Huang C.T., Kowalski J., Blackford A., Horton M.R., Drake C., Schwartz R.H., Powell J.D. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat. Immunol. 2005, 6:472-480.
69. Sánchez-Fidalgo S., Cárdeno A., Villegas I., Talero E., de la Lastra C.A. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur. J. Pharmacol. 2010, 633:78-84.
70. Schug T.T., Xu Q., Gao H., Peres-da-Silva A., Draper D.W., Fessler M.B., Purushotham A., Li X. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol. Cell. Biol. 2010, 30:4712-4721.
71. Schwartz R.H. T cell clonal anergy. Curr. Opin. Immunol. 1997, 9:351-357.
72. Schwartz R.H. T cell anergy. Annu. Rev. Immunol. 2003, 21:305-334.
73. Sen M. Wnt signalling in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:708-713.
74. Shakibaei M., Buhrmann C., Mobasheri A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-κB ligand (RANKL) activation of NF-κB signaling and inhibit osteoclastogenesis in bone-derived cells. J. Biol. Chem. 2011, 286:11492-11505.
75. Simmonds R.E., Foxwell B.M. Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47:584-590.
76. Sloan-Lancaster J., Evavold B.D., Allen P.M. Th2 cell clonal anergyas a consequence of partial activation. J. Exp. Med. 1994, 180:1195-1205.
77. Sloan-Lancaster J., Shaw A.S., Rothbard J.B., Allen P.M. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 1994, 79:913-922.
78. Solomon J.M., Pasupuleti R., Xu L., McDonagh T., Curtis R., DiStefano P.S., Huber L.J. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell. Biol. 2006, 26:28-38.
79. Stahl M., Dijkers P.F., Kops G.J., Lens S.M., Coffer P.J., Burgering B.M., Medema R.H. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J. Immunol. 2002, 168:5024-5031.
80. Stamp L.K., James M.J., Cleland L.G. Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis?. Immunol. Cell Biol. 2004, 82:1-9.
81. -/- mice. Aging (Albany NY) 2010, 2:353-360.
82. Sutmuller R., Garritsen A., Adema G.J. Regulatory T cells and toll-like receptors: regulating the regulators. Ann. Rheum. Dis. 2007, 66(Suppl. 3):iii91-iii95.
83. Tak P.P. Chemokine inhibition in inflammatory arthritis. Best Pract. Res. Clin. Rheumatol. 2006, 20:929-939.
84. + T lymphocytes. J. Immunol. 2007, 179:7305-7315.
85. Turka L.A., Linsley P.S., Lin H., Brady W., Leiden J.M., Wei R.Q., Gibson M.L., Zheng X.G., Myrdal S., Gordon D. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection invivo. Proc. Natl. Acad. Sci. USA 1992, 89:11102-11105.
86. Ullman K.S., Northrop J.P., Admon A., Crabtree G.R. Jun familymembers are controlled by a calcium-regulated, cyclosporin A-sensitive signaling pathway in activated T lymphocytes. Genes Dev. 1993, 7:188-196.
87. Venuprasad K. Cbl-b and itch: key regulators of peripheral T-cell tolerance. Cancer Res. 2010, 70:3009-3012.
88. Villalba J.M., Alcain F.J. Sirtuin activators and inhibitors. Biofactors 2012, 38:349-359.
89. Wang F.M., Chen Y.J., Ouyang H.J. Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation. Biochem. J. 2010, 433:245-252.
90. Xuzhu G., Komai-Koma M., Leung B.P., Howe H.S., McSharry C., McInnes I.B., Xu D. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann. Rheum. Dis. 2012, 71:129-135.
91. Yamamoto Y., Gaynor R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 2001, 107:135-142.
92. Yang S.-R., Wright J., Bauter M., Seweryniak K., Kode A., Rahman I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-κB in macrophages invitro and in rat lungs invivo: implications for chronic inflammation and aging. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292:L567-L576.
93. Yavuz S., Elbir Y., Tulunay A., Eksioglu-Demiralp E., Direskeneli H. Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcet's disease etiopathogenesis. Rheumatol. Int. 2008, 28:401-406.
94. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., Mayo M.W. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23:2369-2380.
95. Yuan J., Minter-Dykhouse K., Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J. Cell Biol. 2009, 185:203-211.
96. Yuan Z., Zhang X., Sengupta N., Lane W.S., Seto E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol. Cell 2007, 27:149-162.
97. Zhang J., Lee S.M., Shannon S., Gao B., Chen W., Chen A., Divekar R., McBurney M.W., Braley-Mullen H., Zaghouani H., Fang D. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J. Clin. Invest. 2009, 119:3048-3058.
98. Zhang R., Chen H.Z., Liu J.J., Jia Y.Y., Zhang Z.Q., Yang R.F., Zhang Y., Xu J., Wei Y.S., Liu D.P., Liang C.C. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J. Biol. Chem. 2010, 285:7097-7110.